Pazufloxacin - Lees Pharmaceutical HoldingsAlternative Names: Pazufloxacin mesilate - Lees Pharmaceutical Holdings
Latest Information Update: 10 Nov 2015
At a glance
- Originator Lees Pharmaceutical Holdings
- Class Antibacterials; Fluoroquinolones; Oxazines; Small molecules
- Mechanism of Action Type II DNA topoisomerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Otitis media
Most Recent Events
- 01 Jul 2015 Phase-I clinical trials in Otitis media in China (Otic) (NCT02592096)